Among them, 378 patients (74.0%) had HR-positive, HER2-negative tumors, 74 patients (14.5%) had triple-negative breast cancer (TNBC), and 59 patients (11.5%) had HER2-positive tumors. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.